for the Period Ended 28 February 2023
Directors report | |
Profit and loss | |
Balance sheet | |
Additional notes | |
Community Interest Report |
Directors' report period ended
The directors present their report with the financial statements of the company for the period ended 28 February 2023
Directors
The directors shown below have held office during the period of
23 March 2022 to 28 February 2023
The director shown below has held office during the period of
23 March 2022 to 24 February 2023
The directors shown below have held office during the period of
23 March 2022 to 23 February 2023
The director shown below has held office during the whole of the period from
23 February 2022 to 28 February 2023
The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006
This report was approved by the board of directors on
And signed on behalf of the board by:
Name:
Status: Director
for the Period Ended
2023 | ||
---|---|---|
| £ | |
Turnover: | | |
Cost of sales: | | |
Gross profit(or loss): | | |
Distribution costs: | | |
Administrative expenses: | ( | |
Other operating income: | | |
Operating profit(or loss): | ( | |
Interest receivable and similar income: | | |
Interest payable and similar charges: | | |
Profit(or loss) before tax: | ( | |
Tax: | | |
Profit(or loss) for the financial year: | ( |
As at
Notes | 2023 | ||
---|---|---|---|
| £ | ||
Fixed assets | |||
Intangible assets: | | ||
Tangible assets: | | ||
Investments: | | ||
Total fixed assets: | | ||
Current assets | |||
Stocks: | | ||
Debtors: | | ||
Cash at bank and in hand: | | ||
Investments: | | ||
Total current assets: | | ||
Prepayments and accrued income: | | ||
Creditors: amounts falling due within one year: | | ||
Net current assets (liabilities): | | ||
Total assets less current liabilities: | | ||
Creditors: amounts falling due after more than one year: | | ||
Provision for liabilities: | | ||
Accruals and deferred income: | ( | ||
Total net assets (liabilities): | ( | ||
Members' funds | |||
Profit and loss account: | ( | ||
Total members' funds: | ( |
The notes form part of these financial statements
This report was approved by the board of directors on
and signed on behalf of the board by:
Name:
Status: Director
The notes form part of these financial statements
for the Period Ended 28 February 2023
Basis of measurement and preparation
Other accounting policies
for the Period Ended 28 February 2023
2023 | ||
---|---|---|
Average number of employees during the period | |
The company exists to provide a community of practice for people interested in advancing person-centred healthcare practice, policy, strategy and research. Health care practitioners and users of health services and systems who are engaged in the development of effective evidence-informed healthcare are the key focus. This includes multidisciplinary clinicians (e.g. doctors, nurses, allied healthcare practitioners), policy makers, managers, leaders, teachers, researchers, students and administrators; as well as persons who are concerned with advocating on behalf of those persons who use healthcare services.In the period of this report, we have engaged the community in co-designing our strategic plan for the next 5 years. This has resulted in the identification of 4 key workstreams that are now being progressed by members of the company and led by Directors and other colleagues. The four workstreams are:- Marketing and communication- Research collaborations- Programmes to develop knowledge, skills and expertise- Knowledge sharingA plan of activity is being developed and will kick-off in January 2024.
The stakeholders are all those who are paid members of the company. Members are either individuals or departments in organisations committed to developing person-centred healthcare. The stakeholders are involved in all aspects of the company and ways of working. We hold two whole company meetings each year as well as an AGM in May and members contribute actively to shaping these agendas.
No remuneration was received
No transfer of assets other than for full consideration
This report was approved by the board of directors on
16 November 2023
And signed on behalf of the board by:
Name: Professor Brendan McCormack
Status: Director